205 related articles for article (PubMed ID: 28046094)
21. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
22. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.
Rideg O; Háber A; Botz L; Szücs F; Várnai R; Miseta A; Kovács GL
Cell Biochem Funct; 2011 Oct; 29(7):562-8. PubMed ID: 21826689
[TBL] [Abstract][Full Text] [Related]
23. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
[TBL] [Abstract][Full Text] [Related]
24. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
[TBL] [Abstract][Full Text] [Related]
25. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
[TBL] [Abstract][Full Text] [Related]
26. Genetic variation of cytochrome P450 in Uyghur Chinese population.
Qi G; Li D; Zhang X
Drug Metab Pharmacokinet; 2018 Feb; 33(1):55-60. PubMed ID: 29233455
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Allele Genotyping in Critical Pharmacogenes Reduces Residual Clinical Risk in Diverse Populations.
Luo S; Jiang R; Grzymski JJ; Lee W; Lu JT; Washington NL
Clin Pharmacol Ther; 2021 Sep; 110(3):759-767. PubMed ID: 33930192
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
Alshabeeb MA; Alyabsi M; Paras B
Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
[TBL] [Abstract][Full Text] [Related]
29. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
31. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study.
Dodgen TM; Hochfeld WE; Fickl H; Asfaha SM; Durandt C; Rheeder P; Drögemöller BI; Wright GE; Warnich L; Labuschagne CD; van Schalkwyk A; Gaedigk A; Pepper MS
BMC Med Genet; 2013 Jan; 14():20. PubMed ID: 23356658
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
33. Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients.
Niedrig DF; Rahmany A; Heib K; Hatz KD; Ludin K; Burden AM; Béchir M; Serra A; Russmann S
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361984
[TBL] [Abstract][Full Text] [Related]
34. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.
Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC
Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444
[TBL] [Abstract][Full Text] [Related]
35. Unique Genotyping Protocol of CYP2D6 Allele Frequency Using Real Time Quantitative PCR from Japanese Healthy Women.
Kisoi M; Imai M; Yamamura M; Sakaguchi Y; Murata S; Ichikawa A; Kinoshita K
Biol Pharm Bull; 2020; 43(5):904-907. PubMed ID: 32378566
[TBL] [Abstract][Full Text] [Related]
36. Genetic insight into cytochrome P450 in Chinese from the Chinese Millionome Database.
Qi G; Han C; Sun Y; Zhou Y
Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):341-352. PubMed ID: 31661191
[TBL] [Abstract][Full Text] [Related]
37. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
38. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
40. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
